Skip to content

Transfemoral Transcatheter Aortic Valve Implantation With or Without Predilation of the Aortic Valve (EASE-IT TF)

Transfemoral Transcatheter Aortic Valve Implantation With or Without Predilation of the Aortic Valve (EASE-IT TF)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02760771
Acronym
EASE-IT-TF
Enrollment
196
Registered
2016-05-04
Start date
2016-05-31
Completion date
2017-12-31
Last updated
2018-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aortic Stenosis

Keywords

THV (trans-catheter heart valve), severe aortic stenosis, pre-dilation, rapid pacing, BAV (balloon artery valvuloplasty

Brief summary

Prior to the deployment of transcatheter heart valves (THV), balloon aortic valvuloplasty (BAV) is often performed under rapid right ventricular pacing (burst \>180 bpm) with the induction of a functional cardiac arrest for up to 30 seconds. Aortic valve predilation aims at facilitating the crossing of the aortic annulus, accurate valve positioning and does also provide information on the anatomy of the valve complex. However, BAV has been shown to have a number of potentially detrimental effects. There is limited experience for the balloon expandable Edwards THV on the need for predilation (BAV). Experience so far has only been documented from smaller, uncontrolled case series. The investigators aim to document the incidence of several kinds of complications in a large, multicenter registry / prospective controlled cohort study to identify associations between patient related variables and outcomes.

Detailed description

Aortic valve predilation aims at facilitating the crossing of the aortic annulus, accurate valve positioning and does also provide information on the anatomy of the valve complex. However, BAV has been shown to have a number of potentially detrimental effects, such as: * Functional cardiac arrest induced by rapid pacing leads to transient coronary, cerebral, and renal ischemia. * In patients with a reduced left ventricular ejection fraction (LVEF), prolonged cardiac depression after rapid pacing is observed and may result in hemodynamic failure and systemic inflammatory response syndrome (SIRS). Both are associated with a high periprocedural mortality. * BAV has been identified as a major source of thrombotic and valvular material, thus increasing the risk for coronary obstruction with subsequent myocardial infarction and/or stroke. * The local trauma in the left-ventricular outflow tract caused by BAV may potentially contribute to aortic root rupture. The investigators aim to document the incidence of cerebrovascular complications, paravalvular leakage and operative outcomes in a large, multicenter registry / prospective controlled cohort study to identify associations between patient related variables and outcomes.

Interventions

OTHERwith BAV

balloon dilation of the aortic valve prior to implantation of the THV

no balloon dilation of the aortic valve prior to implantation of the THV

Sponsors

Institut für Pharmakologie und Präventive Medizin
Lead SponsorNETWORK

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Signed informed consent * Males or females * At least 18 years of age

Exclusion criteria

* Logistic EuroSCORE I \>40% * Mitral or tricuspid valvular insufficiency (\> grade II) * Previous aortic valve replacement * Uncontrolled atrial fibrillation * Left ventricular or atrial thrombus by echocardiography * High probability of non-adherence to the follow-up requirements (due to social, psychological or medical reasons) * Patients with mobile structures on the leaflets * Need for a cerebral protection device

Design outcomes

Primary

MeasureTime frame
Combination of all-cause mortality, stroke, non-fatal myocardial infarction, acute kidney injury, or pacemaker implantationwithin 30 days after TAVI

Secondary

MeasureTime frame
All-cause mortalitywithin 30 days after TAVI
Strokewithin 30 days after TAVI
Non-fatal myocardial infarctionwithin 30 days after TAVI
pacemaker implantationwithin 30 days after TAVI
acute kidney injurywithin 30 days after TAVI

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 11, 2026